+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Pheno- and genotyping the prescription of drugs metabolized by CYP2D6



Pheno- and genotyping the prescription of drugs metabolized by CYP2D6



Bulletin of Experimental Biology and Medicine 134(2): 159-160



Mutant alleles CYP2D63 and CYP2D64 were detected by PCR in 33 individuals. All examinees were given 50 mg methoprolol (orally). Plasma concentrations of the drug and its major metabolite was determined by high performance liquid chromatography and arterial pressure and heart rate were monitored. The rate of methoprolol metabolism was significantly lowered in subjects with CYP2D64 mutation. This determined blood pressure decrease and bradycardia in these subjects after drug intake.

(PDF emailed within 0-6 h: $19.90)

Accession: 046973157

Download citation: RISBibTeXText

PMID: 12459840

DOI: 10.1023/a:1021188315536


Related references

A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metabolism and Disposition: the Biological Fate of Chemicals 41(4): 801-813, 2013

A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. British Journal of Clinical Pharmacology 74(5): 873-885, 2013

Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 44(4): 309-319, 2014

Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. Clinical Laboratory 57(11-12): 887-893, 2012

The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. Journal of Clinical Psychopharmacology 27(3): 241-245, 2007

Genotyping for the polymorphic CYP2D6 A tool for individualized dosage of psychotropic drugs. Therapie (Paris) 0(SUPPL ): 60, 1995

CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene. Pharmacogenomics 13(8): 951-954, 2013

Standard CYP2D6 genotyping procedures fail for the CYP2D6*5 and duplication alleles when hair roots are used as a source of DNA. Clinica Chimica Acta 329(1-2): 61-68, March, 2003

CYP2D6 polymorphisms and cancer risk Potential genotyping artifacts due to high homology with CYP2D6 pseudogenes. Proceedings of the American Association for Cancer Research Annual Meeting 40: 468, March, 1999

Novel structure of the CYP2D6 gene that confuses genotyping for the CYP2D6*5 allele. Drug Metabolism and Pharmacokinetics 20(5): 345-350, 2005

CYP2D6-genotyping in clinical practice Impact of genotyp on serum concentrations of psychiatric relevant CYP2D6-substrates. Pharmacopsychiatry 36(5): 268, September, 2003

The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochemical Pharmacology 64(9): 1387-1398, 2002

Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Human Psychopharmacology 24(4): 301-308, 2009